HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?
Rosalba Torrisi, Flavia Jacobs, Chiara Miggiano, Rita De Sanctis, Armando Santoro
Abstract
This is a critical narrative review focusing on HR+/human epidermal growth factor receptor 2-negative (HER2–) de novo metastatic breast cancer in terms of genomic, biological, pathological, and clinical features and outcomes after systemic and locoregional treatments, outlining differences with recurrent metastatic breast cancer.
Topics & Concepts
Metastatic breast cancerMedicineCancerOncologyBreast cancerInternal medicineAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysBreast Cancer Treatment Studies